Production of GLP erythromer for IND enabling animal studies
Ended Other Transaction Agreement Awarded
- Contract number
- HR00112590241
- Awardee
-
Kalocyte Inc. UEI MJMKM31FM667
- Awarding agency
-
Defense Advanced Research Projects Agency
Department of Defense
- Obligated
- $1,799,993
Award facts
- Contract value 100% obligated
- $1,799,993.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- Not on record
- Set-aside
- No set-aside
- Competition
- Competed Broad Agency Announcement
- Pricing
- Other
- Place of performance
- Baltimore, MD 21201, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Advanced Research Projects Agency (DARPA) awarded an $1.8M Other Transaction Agreement to Kalocyte Inc. on August 14, 2025, for the production of Good Laboratory Practice (GLP)-compliant ErythroMer for Investigational New Drug (IND) enabling animal studies. The contract, which is not subject to a set-aside designation, extends through August 14, 2026, and will be performed in Baltimore, Maryland. Kalocyte Inc., a small disadvantaged biotech firm, is developing ErythroMer, a bio-inspired artificial red blood cell substitute designed to address life-threatening blood loss in military and civilian trauma scenarios.
This effort builds on Kalocyte's prior federal investments from the Defense Health Agency and the National Institutes of Health to advance the ErythroMer technology platform. The company has established partnerships with the University of Illinois at Urbana-Champaign for manufacturing and Washington University in St. Louis for in vivo efficacy validation. Under this contract, Kalocyte will produce GLP-grade ErythroMer necessary to support regulatory submissions, including animal studies required for IND applications. The deliverables represent a critical transition from research and development to pharmaceutical manufacturing standards, positioning the technology for potential clinical advancement as a next-generation resuscitation fluid for hemorrhagic shock management across multiple trauma scenarios.
Quick answers
Who was awarded contract HR00112590241?
HR00112590241 was awarded to Kalocyte Inc. by Defense Advanced Research Projects Agency (Department of Defense) on August 14, 2025.
How much is contract HR00112590241 worth?
The government has obligated $1,799,993 on HR00112590241.
Was contract HR00112590241 competed?
The extent of competition for HR00112590241 was competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award